Daridorexant Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 25 mg, 50 mg

Reference Brands: Quviviq (USA/EU)

Category: Neurology

Product Description:

Daridorexant, marketed under the brand name Quviviq, is an oral medication approved for the treatment of insomnia in adults, specifically for those experiencing difficulties with sleep onset and/or sleep maintenance. As a dual orexin receptor antagonist (DORA), daridorexant works by selectively blocking orexin receptors OX1 and OX2, helping to regulate the sleep-wake cycle and promote restful, continuous sleep.

Clinical studies have demonstrated that daridorexant significantly improves multiple measures of sleep. At doses of 25 to 50 mg, it reduces latency to persistent sleep (LPS) by 6 to 12 minutes, decreases wake after sleep onset (WASO) by 10 to 23 minutes, and increases subjective total sleep time (TST) by 10 to 22 minutes compared with placebo. Furthermore, at the 50 mg dose, daridorexant has been shown to enhance daytime functioning, supporting better alertness and cognitive performance during waking hours.

Taken orally once daily before bedtime, daridorexant provides a modern, targeted approach to insomnia management with a favorable tolerability profile. It offers patients a safe and effective option for improving both nighttime sleep quality and overall daytime well-being.